DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place becaus...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Kaltenbach, Robert F., Trainor, George, Getman, Daniel, Harris, Greg, Garber, Sena, Cordova, Beverly, Bacheler, Lee, Jeffrey, Susan, Logue, Kelly, Cawood, Pamela, Klabe, Ronald, Diamond, Sharon, Davies, Marc, Saye, Joanne, Jona, Janan, Erickson-Viitanen, Susan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2001
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90777/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11600351/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.11.3021-3028.2001
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!